Benjamin Sredni

6.6k citations

165 papers · 5.3k indexed · 1 hit paper · h-index 42

Impact in

Toxicology top 0.1%
- Organoselenium and organotellurium chemistry
Immunology top 1%
- T-cell and B-cell Immunology
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses

Papers in

Toxicology 20
- Organoselenium and organotellurium chemistry 20
Immunology 69
- Immune Cell Function and Interaction 19
- T-cell and B-cell Immunology 17
- Immunotherapy and Immune Responses 16
- Immune Response and Inflammation 12
- Macrophage Migration Inhibitory Factor 10

Co-authors: Michael Albeck Yona Kalechman Ronald H. Schwartz Uzi Gafter F. Shalit Hagai Ligumsky Ido Wolf Hannah Kanety
Journals: The Journal of Immunology (9 papers)Cellular Immunology (5 papers)Nature (5 papers)Frontiers in Immunology (3 papers)Clinical & Experimental Immunology (3 papers)
Partner nations: Israel United States Canada

In The Last Decade

Benjamin Sredni

164 papers receiving 5.1k citations

Hit Papers

align trajectories log scale

Cyclophosphamide Triggers Follicle Activation and “Burnout”; AS101 Prevents Follicle Loss and Preserves Fertility 2013 · 403 citations

Peers

Countries citing papers authored by Benjamin Sredni

Since Specialization

Citations

This map shows the geographic impact of Benjamin Sredni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Benjamin Sredni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Benjamin Sredni more than expected).

Fields of papers citing papers by Benjamin Sredni

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Benjamin Sredni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Benjamin Sredni. The network helps show where Benjamin Sredni may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Benjamin Sredni, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Benjamin Sredni Line = papers co-authored together Benjamin Sredni links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Inhibition of α4β1 Integrin Activity by Small Tellurium Compounds Regulates PD-L1 Expression and Enhances Antitumor Effects International Journal of Biological Sciences ·D.I. Rushton, Yona Kalechman, Mullā ʿAlī al-Qārī, Shelly G. Hazle, J. H. Kanzelmeyer, A. M. da Silva, Hagit Hauschner, R. Schiefer, Tal Cohen, Agata Schlesinger, 方明, Mira Barda‐Saad, Felicia Burvall, Michael Albeck, Dan L. Longo, Benjamin Sredni	2024	1
2	Novel Strategy to Regulate PD-L1 Expression and Enhance Anti-Tumor Effect The Journal of Immunology ·Benjamin Sredni, D.I. Rushton, Mullā ʿAlī al-Qārī, 焦艳丽, 方明, Yona Kalechman	2023	0
3	The Small Tellurium Compound AS101 Ameliorates Rat Crescentic Glomerulonephritis: Association with Inhibition of Macrophage Caspase-1 Activity via Very Late Antigen-4 Inactivation Frontiers in Immunology ·Qing-qing Huang, Yona Kalechman, Emine Begüm AKKUŞ, Uzi Gafter, Rachel R Caspi, Benjamin Sredni	2017	7
4	The small tellurium-based compound SAS suppresses inflammation in human retinal pigment epithelium. PubMed ·Rima Dardik, Tami Livnat, Gilad Halpert, Shayma Jawad, Yael Nisgav, THEODORE K. RICE, Baoying Liu, Robert B. Nussenblatt, Dov Weinberger, Benjamin Sredni	2016	16
5	Sensitizing B- and T- cell Lymphoma Cells to Paclitaxel/Abraxane–Induced Death by AS101 via Inhibition of the VLA-4–IL10–Survivin Axis Molecular Cancer Research ·Sara Navarro-Lalanda, Yona Kalechman, Michael Albeck, Dan L. Longo, Benjamin Sredni	2014	16
6	Redox Modulation of Adjacent Thiols in VLA-4 by AS101 Converts Myeloid Leukemia Cells from a Drug-Resistant to Drug-Sensitive State Cancer Research ·Andrew R. Nye, Emine Begüm AKKUŞ, Alain Berrébi, Maor H. Pauker, Felicia Burvall, Alon Silberman, Michael Albeck, Dan L. Longo, Yona Kalechman, Benjamin Sredni	2014	60
7	The effect of the novel tellurium compound AS101 on autoimmune diseases Autoimmunity Reviews ·Gilad Halpert, Benjamin Sredni	2014	55
8	The anti-inflammatory effects of the tellurium redox modulating compound, AS101, are associated with regulation of NFκB signaling pathway and nitric oxide induction in macrophages Journal of Inflammation ·И. А. Аллилуев, Gilad Halpert, Michael Albeck, Benjamin Sredni	2010	53
9	Induction therapy in a multiple myeloma mouse model using a combination of AS101 and melphalan, and the activity of AS101 in a tumor microenvironment model Experimental Hematology ·Cai Ya-guo, М.Ю. Смирнов, Michael Albeck, Alpha Peled, Nechama Haran‐Ghera, Benjamin Sredni	2009	14
10	Rapamycin and curcumin induce apoptosis in primary resting B chronic lymphocytic leukemia cells Leukemia & lymphoma ·Zeeshan Haider, Eitan Okun, Alain Berrébi, Lev Shvidel, Aviral Srivastava, Benjamin Sredni, Uri Nir	2009	23
11	The immunomodulator AS101 induces growth arrest and apoptosis in Multiple Myeloma: Association with the Akt/Survivin pathway Biochemical Pharmacology ·Cai Ya-guo, Perry King, Merav Weil, Michael Albeck, Alpha Peled, Jeremy Don, Nechama Haran‐Ghera, Benjamin Sredni	2006	37
12	Upregulation of carp GDNF mRNA by the immunomodulator AS101 Developmental & Comparative Immunology ·Eitan Okun, М.Ю. Смирнов, Michael Albeck, Benjamin Sredni, Ramy R. Avtalion	2005	9
13	Inhibition of Interleukin-10 by the Immunomodulator AS101 Reduces Mesangial Cell Proliferation in Experimental Mesangioproliferative Glomerulonephritis Journal of Biological Chemistry ·Yona Kalechman, Uzi Gafter, Talia Weinstein, Avry Chagnac, Hiroko Kominanmi, Ana Tobar, Michael Albeck, Benjamin Sredni	2004	39
14	Anti-IL-10 Therapeutic Strategy Using the Immunomodulator AS101 in Protecting Mice from Sepsis-Induced Death: Dependence on Timing of Immunomodulating Intervention The Journal of Immunology ·Yona Kalechman, Uzi Gafter, Rivka Gal, N Emami Meybodi, Donghong Yan, Michael Albeck, Benjamin Sredni	2002	112
15	β-Amyloid peptide induces tumor necrosis factor-α and nitric oxide production in murine macrophage cultures Neuroreport ·F. Shalit, Benjamin Sredni, Ekoué David Dosseh, Gila Kazimirsky, Chaya Brodie, M. Huberman	1997	13
16	Suppressed Cell-Mediated Immunity and Monocyte and Natural Killer Cell Activity Following Allogeneic Immunization of Women with Spontaneous Recurrent Abortion Journal of Clinical Immunology ·Ezra Arya Wijaya, Benjamin Sredni, Jacob Segal, Yona Kalechman	1997	33
17	Muscle cells produce a low molecular weight factor with anti-cancer activity Clinical & Experimental Metastasis ·M Djaldetti, Benjamin Sredni, R. Zigelman, Suzana Popescu, Pnina Fishman	1996	33
18	Enhancing Effects of Autologous Erythrocytes on Human or Mouse Cytokine Secretion and IL-2R Expression Cellular Immunology ·Yona Kalechman, Austin Cho, Uzi Gafter, Benjamin Sredni	1993	27
19	Inhibition of the Reverse Transcriptase Activity and Replication of Human Immunodeficiency Virus Type 1 by AS 101 In Vitro AIDS Research and Human Retroviruses ·A Vonsover, Shoshana Loya, Benjamin Sredni, Michael Albeck, T. Gotlieb‐Stematsky, Xiqiang Dang, Amnon Hizi	1992	17
20	Effect of dexamethasone on IL-1 and IL-3-LA release by unstimulated human mononuclear cells Biomedicine & Pharmacotherapy ·Ruth Djaldetti, Pnina Fishman, Sharman Charles, Benjamin Sredni, M Djaldetti	1990	6

About Benjamin Sredni

Benjamin Sredni is a scholar working on Toxicology, Immunology, Biological Psychiatry, Transplantation and Hematology, having authored 165 papers that have together received 5.3k indexed citations. Recurring topics across this work include Organoselenium and organotellurium chemistry (20 papers), Immune Cell Function and Interaction (19 papers), T-cell and B-cell Immunology (17 papers), Immunotherapy and Immune Responses (16 papers), Immune Response and Inflammation (12 papers), Monoclonal and Polyclonal Antibodies Research (11 papers), Systemic Lupus Erythematosus Research (10 papers) and Macrophage Migration Inhibitory Factor (10 papers). The work is most often cited by research in Toxicology (680 citations), Immunology (1.6k citations), Biological Psychiatry (138 citations), Reproductive Medicine (396 citations) and Transplantation (115 citations). Benjamin Sredni has collaborated with scholars based in Israel, United States and Canada. Frequent co-authors include Michael Albeck, Yona Kalechman, Ronald H. Schwartz, Uzi Gafter, F. Shalit, Hagai Ligumsky, Ido Wolf, Hannah Kanety, M. Huberman and Edna Kott. Their work appears in journals such as The Journal of Immunology, Cellular Immunology, Nature, Frontiers in Immunology and Clinical & Experimental Immunology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact